Sanford Burnham Institute for Medical Research

sbpdiscovery.org
La Jolla, CA, United States

The Sanford-Burnham Medical Research Institute, previously Burnham Institute for Medical Research, is a non-profit medical research institute with locations in La Jolla, California, Orlando, Florida, and Santa Barbara, California. There are more than 850 scientists at Sanford-Burnham; they work on the fundamental molecular causes of various diseases, with research including topics such as cancer, neuroscience, stem cell research, diabetes and obesity.Research at Sanford-Burnham is supported by funding from National Institutes of Health, National Cancer Institute, and Juvenile Diabetes Research Foundation among others, and partnerships with pharmaceutical companies such as Johnson & Johnson Pharmaceutical Research and Development. In 2008, Sanford-Burnham was awarded a $97.9 million grant by NIH to establish a high-throughput screening screening center. Wikipedia.


Time filter

Source Type

Patent
Sanford Burnham Institute for Medical Research | Date: 2016-11-29

Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPB), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.


Patent
Mandala Biosciences,LLC, Bio Time Inc. and Sanford Burnham Institute for Medical Research | Date: 2015-11-02

The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.


Patent
Sanford Burnham Institute for Medical Research | Date: 2017-04-19

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.


Patent
Sanford Burnham Institute for Medical Research | Date: 2017-05-17

Embodiments of the methods and compositions provided herein relate to inducing hair growth in a subject. Some embodiments include screening for agents to modulate hair growth.


Patent
Southern Research Institute and Sanford Burnham Institute for Medical Research | Date: 2017-02-06

Provided is a method for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus, as well as novel compounds that are useful in the method.


Patent
Sanford Burnham Institute for Medical Research | Date: 2017-05-17

The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.


Patent
Vascular Biosciences, Sanford Burnham Institute for Medical Research, Mann, Ruoslahti and Komatsu | Date: 2017-06-14

Compositions and methods useful for delivery of targeted therapies for pulmonary arterial hypertension, sepsis, cancer and cachexia. The compositions and methods are based on peptide pharmacophores that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. Peptide pharmacophores may selectively target tumor vasculature, regenerating tissue, wounded tissue, inflamed tissue, fibrotic tissue, remodeled tissue, tissue characterized by elevated heparanase levels, and have the ability to internalize into such diseased cells.


Patent
Daiichi Sankyo and Sanford Burnham Institute for Medical Research | Date: 2017-04-06

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R^(1 )represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R^(2 )and R^(3 )are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R^(4 )and R^(5 )are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R^(6 )represents a hydrogen atom or the like, each R^(7 )may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents CH, C(R^(7)), or N, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.


Patent
Salk Institute for Biological Studies, Sanford Burnham Institute for Medical Research and Yale University | Date: 2017-07-05

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.


Wolf D.A.,Sanford Burnham Institute for Medical Research
Cancer Cell | Year: 2014

A series of recent reports has suggested PGC1α-driven upregulation of mitochondrial oxidative phosphorylation as a selective vulnerability of drug-resistant cancers. Accordingly, chemical inhibitors of respiration led to selective eradication of such cancer cells due to their preferential sensitivity to mitochondrial production of reactive oxygen species. These insights create a timely opportunity for a biomarker guided application of already existing and newly emerging mitochondrial inhibitors in recurrent drug-resistant cancer, including lymphomas, melanomas, and other malignant diseases marked by increased mitochondrial respiration. © 2014 Elsevier Inc.

Loading Sanford Burnham Institute for Medical Research collaborators
Loading Sanford Burnham Institute for Medical Research collaborators